Bharat V. Daftary, chairman and MD of Bharat Serums & Vaccines (BSV), a biopharmaceutical company with R&D units in USA, Germany & India and with a presence in over 76 countries, provides insights into the biotech landscape in India and its expectations for the fertility and women’s health markets. He also highlights BSV’s ambitions to develop two new biologicals in the critical care field and the company's enduring commitment to “bring life to life” through the development of differentiated, complex, and highly needed products.
BSV has forged itself a strong reputation as a frontrunner among the Indian pharmaceutical industry. Could you share with us some key achievements and milestones reached by the company?
"Although our company’s headcount is smaller than those of some Indian heavyweights, BSV’s revenues per person places our company as one of the top performing players in the Indian industry. This is due to the quality of our differentiated portfolio of complex products and to our efficient sales monitoring."
